Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03500159CT.gov Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Prostatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rosiptor (this asset) | Aquinox Pharmaceuticals (Canada) Inc. | P2 | CCC · 53 |
| Ningmitai | Xintian Pharmaceutical | P4 | BBB |
| Selenium | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| Palmitic Monoethanolamide | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| Serenoa Repens Extract | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| Tamsulosin | Xintian Pharmaceutical | P4 | BB |
| om-89 [uro-vaxom® ] | AJU Pharm Co., Ltd. | P4 | BB |
| Celecoxib | Xintian Pharmaceutical | P4 | BB |
| Cernilton | University of Giessen | P3 | BB |
+11 more in the Chronic Prostatitis cohort
Other indications for Rosiptor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Interstitial Cystitis | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NingmitaiXintian PharmaceuticalBBB
- SeleniumClinica Urologica Molinette - Città della Saliute e della ScienzaBB
- Palmitic MonoethanolamideClinica Urologica Molinette - Città della Saliute e della ScienzaBB
- Serenoa Repens ExtractClinica Urologica Molinette - Città della Saliute e della ScienzaBB
- TamsulosinXintian PharmaceuticalBB
Citation
Floatz Terminal. Rosiptor in Chronic Prostatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rosiptor-chronic-prostatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →